You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

IBI305

Showing 1 - 25 of 57
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Non-Squamous NSCLC Trial in Shanghai (Sintilimab, IBI305, Pemetrexed)

Recruiting
  • Non-Squamous Non-Small Cell Lung Cancer
  • Shanghai, Shanghai, China
    Shanghai Chest Hospital
Sep 22, 2022

Intrahepatic Cholangiocarcinoma Trial in Tianjin (Sintilimab, IBI305, GEMOX)

Recruiting
  • Intrahepatic Cholangiocarcinoma
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute & Hospital
Feb 22, 2022

Hepatocellular Carcinoma Trial in Wuhan (HAIC, Sintilimab, Bevacizumab Biosimilar IBI305)

Recruiting
  • Hepatocellular Carcinoma
  • Wuhan, Hubei, China
    Union Hospital affiliated to Tongji Medical College of Huazhong
Nov 8, 2022

Ovarian Clear Cell Carcinoma Trial in Wuhan (Sintilimab, Bevacizumab Biosimilar IBI305)

Recruiting
  • Ovarian Clear Cell Carcinoma
  • Wuhan, Hubei, China
    Tongji Hospital of Tongji Medical College, Huazhong University o
Apr 18, 2022

Post-orthotopic Liver Transplantation, Hepatocellular Carcinoma Recurrent Trial in Nanjing (Bevacizumab Biosimilar IBI305)

Not yet recruiting
  • Post-orthotopic Liver Transplantation
  • Hepatocellular Carcinoma Recurrent
  • Bevacizumab Biosimilar IBI305
  • Nanjing, Jiangsu, China
    Jiangsu Province Hospital
May 5, 2022

Non Small Cell Lung Cancer Trial in Tianjin (Osimertinib, Bevacizumab Biosimilar IBI305, Carboplatin)

Recruiting
  • Non Small Cell Lung Cancer
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute and Hospital
Aug 18, 2022

Hepatocellular Carcinoma Trial in Tianjin (HAIC, Sintilimab, Bevacizumab Biosimilar)

Recruiting
  • Hepatocellular Carcinoma
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute & Hospital
Jan 16, 2022

Advanced Hepatocellular Carcinoma Trial in Beijing (Sintilimab+IBI305)

Completed
  • Advanced Hepatocellular Carcinoma
  • Beijing, China
    National Cancer Center/Cancer Hospital, Chinese ACademy of Medic
Jan 29, 2021

Advanced Microsatellite Stable Colorectal Cancer, Metastatic Microsatellite-stable Colorectal Cancer Trial (Sintilimab,

Not yet recruiting
  • Advanced Microsatellite Stable Colorectal Cancer
  • Metastatic Microsatellite-stable Colorectal Cancer
  • (no location specified)
Feb 3, 2021

Hepatocellular Carcinoma Trial in Shanghai (Sintilimab, IBI305, Sorafenib)

Unknown status
  • Hepatocellular Carcinoma
  • Shanghai, Shanghai, China
    Hospital of Fudan University
Jan 21, 2021

Healthy Trial in Changchun (IBI305(Bevacizumab Biosimilar), Avastin(Bevacizumab))

Completed
Has Results
  • Healthy
  • Changchun, Jilin, China
    Jilin University First Hospital
Nov 12, 2020

Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for

Recruiting
  • Hepatocellular Carcinoma Non-resectable
  • HAIC
  • +8 more
  • Quanzhou, Fujian, China
  • +1 more
Jan 26, 2023

Recurrent Brain Tumor Trial in Houston (biological, other, radiation)

Active, not recruiting
  • Recurrent Brain Neoplasm
  • Bevacizumab
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 9, 2022

NSCLC Trial in Guangzhou (Bevacizumab in Combination With Paclitaxel/Carboplatin, IBI305 in Combination with

Completed
Has Results
  • NSCLC
  • Bevacizumab in Combination With Paclitaxel/Carboplatin
  • IBI305 in Combination with Paclitaxel/Carboplatin
  • Guangzhou, Guangdong, China
    Cancer Center; Sun Yat sen University;
Nov 12, 2020

Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for

Recruiting
  • Hepatocellular Carcinoma Non-resectable
  • TACE
  • +8 more
  • Quanzhou, Fujian, China
  • +3 more
Jan 29, 2023

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Completed
Has Results
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +8 more
  • Bevacizumab
  • Irinotecan Sucrosofate
  • Chicago, Illinois
    Northwestern University
Dec 21, 2022

Resectable Hepatocellular Carcinoma, Stage I Hepatocellular Carcinoma AJCC v8, Stage IA Hepatocellular Carcinoma AJCC v8 Trial

Recruiting
  • Resectable Hepatocellular Carcinoma
  • +4 more
  • Atezolizumab
  • +2 more
  • Houston, Texas
  • +1 more
Oct 12, 2022

Fallopian Tube Carcinosarcoma, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma Trial in Buffalo

Not yet recruiting
  • Fallopian Tube Carcinosarcoma
  • +10 more
  • Bevacizumab
  • +4 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Dec 29, 2022

Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIC Lung Cancer AJCC v8 Trial in

Recruiting
  • Metastatic Lung Non-Small Cell Carcinoma
  • +5 more
  • Bevacizumab
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Jul 13, 2022

Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Endometrial Serous Adenocarcinoma Trial in

Not yet recruiting
  • Ovarian Clear Cell Adenocarcinoma
  • +14 more
  • Anti-CD40 Agonist Monoclonal Antibody CDX-1140
  • +4 more
  • Buffalo, New York
  • +1 more
Dec 16, 2022

Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell

Recruiting
  • Locally Advanced Lung Non-Small Cell Carcinoma
  • +9 more
  • Duarte, California
  • +4 more
Aug 17, 2022

Invasive Breast Carcinoma, Triple-Negative Breast Carcinoma Trial in Houston (biological, drug, other)

Active, not recruiting
  • Invasive Breast Carcinoma
  • Triple-Negative Breast Carcinoma
  • Bevacizumab
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Feb 18, 2022

Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Tumor in the Brain, Stage IV Lung Non-Small Cell Cancer AJCC v7

Active, not recruiting
  • Metastatic Lung Non-Small Cell Carcinoma
  • +2 more
  • Bevacizumab
  • +2 more
  • Los Angeles, California
  • +17 more
Jan 27, 2023

Metastatic Colorectal Carcinoma, Metastatic Malignant Tumor in the Liver, Stage IV Colorectal Cancer AJCC v8 Trial (biological,

Not yet recruiting
  • Metastatic Colorectal Carcinoma
  • +3 more
  • Bevacizumab
  • +11 more
  • (no location specified)
May 9, 2023

Metastatic Colorectal Carcinoma, Recurrent Colorectal Carcinoma, Refractory Colorectal Carcinoma Trial in United States (drug,

Active, not recruiting
Has Results
  • Metastatic Colorectal Carcinoma
  • +5 more
  • Phoenix, Arizona
  • +9 more
Jan 5, 2022